Search Results - "Cran, Jordan"

The eEF2 kinase coordinates the DNA damage response to cisplatin by supporting p53 activation by Lim, Jonathan K. M., Samiei, Arash, Delaidelli, Alberto, de Santis, Jessica Oliveira, Brinkmann, Vanessa, Carnie, Christopher J., Radiloff, Daniel, Hruby, Laura, Kahler, Alisa, Cran, Jordan, Leprivier, Gabriel, Sorensen, Poul H.

“…Eukaryotic elongation factor 2 (eEF2) kinase (eEF2K) is a stress-responsive hub that inhibits the translation elongation factor eEF2, and consequently mRNA…”
Get full text

Targeting the tumour vasculature: exploitation of low oxygenation and sensitivity to NOS inhibition by treatment with a hypoxic cytotoxin by Baker, Jennifer H E, Kyle, Alastair H, Bartels, Kirsten L, Methot, Stephen P, Flanagan, Erin J, Balbirnie, Andrew, Cran, Jordan D, Minchinton, Andrew I

“…Many cancer research efforts focus on exploiting genetic-level features that may be targeted for therapy. Tissue-level features of the tumour microenvironment…”
Get full text

Class I HDAC inhibitors enhance YB‐1 acetylation and oxidative stress to block sarcoma metastasis by El‐Naggar, Amal M, Somasekharan, Syam Prakash, Wang, Yemin, Cheng, Hongwei, Negri, Gian Luca, Pan, Melvin, Wang, Xue Qi, Delaidelli, Alberto, Rafn, Bo, Cran, Jordan, Zhang, Fan, Zhang, Haifeng, Colborne, Shane, Gleave, Martin, Mandinova, Anna, Kedersha, Nancy, Hughes, Christopher S, Surdez, Didier, Delattre, Olivier, Wang, Yuzhuo, Huntsman, David G, Morin, Gregg B, Sorensen, Poul H

“…Outcomes for metastatic Ewing sarcoma and osteosarcoma are dismal and have not changed for decades. Oxidative stress attenuates melanoma metastasis, and…”
Get full text

Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment by Baker, Jennifer Hazel Elizabeth, Kyle, Alastair Hugh, Reinsberg, Stefan Alexander, Moosvi, Firas, Patrick, Haley Margaret, Cran, Jordan, Saatchi, Katayoun, Häfeli, Urs, Minchinton, Andrew Ivor

“…Most HER2-positive metastatic breast cancer patients continue to relapse. Incomplete access to all target HER2-positive cells in metastases and tumor tissues…”
Get full text

Abstract B32: Microenvironmental distribution of trastuzumab in metastases and xenograft models is highly heterogeneous and decreases sharply when administered in combination with bevacizumab by Baker, Jennifer H.E., Kyle, Alastair H., Cran, Jordan, Patrick, Haley, Gandolfo, Maria-Jose, Minchinton, Andrew I.

“…Abstract Despite significant success, the response of Her2+ patients to trastuzumab (TzMAb, Herceptin ®) is varied, with many still experiencing tumor…”
Get full text

MBRS-57. TARGETING METABOLIC ADAPTATION IN MYC/MYCN AMPLIFIED PEDIATRIC MEDULLOBLASTOMA AND NEUROBLASTOMA by Delaidelli, Alberto, Negri, Gian Luca, Sidhu, Simran, Cran, Jordan, Remke, Marc, Pfister, Stefan, Kool, Marcel, Taylor, Michael, Maris, John, Leprivier, Gabriel, Sorensen, Poul

“…Abstract BACKGROUND The MYC oncogenes contribute to more than 50% of all human cancers, but their therapeutic targeting has proven challenging. MYC/MYCN…”
Get full text

Abstract 2988: Microenvironmental distribution of trastuzumab is heterogeneous and decreases sharply when administered following a single dose of bevacizumab in Her2+ve xenografts and metastases models by Baker, Jennifer H. E., Kyle, Alastair H., Reinsberg, Stefan A., Moosvi, Firas, Cran, Jordan, Hafeli, Urs, Saatchi, Katayoun, Minchinton, Andrew I.

“…Abstract We have previously shown that trastuzumab distributes heterogeneously within MDA-435-Her2 xenografts. Though peak accumulation occurs 24h after…”
Get full text